Thursday, August 11, 2022
SCIENMAG: Latest Science and Health News
No Result
View All Result
  • Login
  • HOME PAGE
  • BIOLOGY
  • CHEMISTRY AND PHYSICS
  • MEDICINE
    • Cancer
    • Infectious Emerging Diseases
  • SPACE
  • TECHNOLOGY
  • CONTACT US
  • HOME PAGE
  • BIOLOGY
  • CHEMISTRY AND PHYSICS
  • MEDICINE
    • Cancer
    • Infectious Emerging Diseases
  • SPACE
  • TECHNOLOGY
  • CONTACT US
No Result
View All Result
Scienmag - Latest science news from science magazine
No Result
View All Result
Home SCIENCE NEWS Medicine & Health

Anti-HIV drug for adults is safe, effective in children exposed to nevirapine in the womb

November 3, 2015
in Medicine & Health
0
Share on FacebookShare on Twitter

HIV-infected children exposed in the womb to nevirapine, a drug used to prevent mother-to-child HIV transmission, can safely and effectively transition to efavirenz, a similar drug recommended for older children and adults, according to a study funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), part of the National Institutes of Health.

Efavirenz is used as part of HIV therapy for adults and children older than three years of age. A different class of anti-HIV drugs, lopinavir/ritonavir, is recommended for infants and young children. Switching children to efavirenz offers several advantages, including once-daily dosing, easier storage, better taste, and lower cost. Prior to the new study, however, doctors lacked guidance on when to switch to efavirenz. There also was concern that efavirenz may be less effective in children exposed to nevirapine because the drugs attack HIV in similar ways, leading to potential drug resistance.

Researchers led by Louise Kuhn, Ph.D., of Columbia University, conducted a randomized clinical trial in Johannesburg, South Africa, to evaluate whether or not nevirapine-exposed children, who have their infection under control, can transition to efavirenz without risk of the virus rebounding and becoming detectable in blood. Approximately 300 boys and girls at least 3 years old were followed for 48 weeks, with half continuing on lopinavir/ritonavir and the other half switching to efavirenz.

The team found that both groups of children had similar rates of viral rebound–26 in the efavirenz group and 42 in the lopinavir/ritonavir group, suggesting that switching to efavirenz is effective. Furthermore, the efavirenz group had higher levels of CD4 T cells, key immune cells wiped out by HIV, and better liver function, suggesting that efavirenz is less toxic and safer than lopinavir/ritonavir. The researchers are currently conducting a follow-up study to evaluate the long-term effects of switching to efavirenz.

###

Share25Tweet16Share4ShareSendShare
  • Quaise_Energy_Gyrotron.png

    Experts optimistic about converting coal plants to production of clean geothermal energy

    105 shares
    Share 42 Tweet 26
  • Order up: new study reveals importance of liquid structural ordering in crystallization

    79 shares
    Share 32 Tweet 20
  • Study finds second primary lung cancer is 4 percent and as high as 8 percent among surgery patients

    78 shares
    Share 31 Tweet 20
  • United Kingdom-based smoking cessation program reports that 30 percent of support in a lung cancer screening program: the Yorkshire Enhanced Stop Smoking Study (YESS)

    77 shares
    Share 31 Tweet 19
  • NELSON trial protocol more sensitive than NLST and may increase the benefits of lung cancer screening, while reducing unnecessary follow-up procedures

    77 shares
    Share 31 Tweet 19
  • Sub-lobar surgery for peripheral non-small cell lung cancer non-inferior to lobectomy

    76 shares
    Share 30 Tweet 19
ADVERTISEMENT

About us

We bring you the latest science news from best research centers and universities around the world. Check our website.

Latest NEWS

Experts optimistic about converting coal plants to production of clean geothermal energy

A role for cell ‘antennae’ in managing dopamine signals in the brain

The walk of Japanese children develops differently from children in other countries

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 193 other subscribers

© 2022 Scienmag- Science Magazine: Latest Science News.

No Result
View All Result
  • HOME PAGE
  • BIOLOGY
  • CHEMISTRY AND PHYSICS
  • MEDICINE
    • Cancer
    • Infectious Emerging Diseases
  • SPACE
  • TECHNOLOGY
  • CONTACT US

© 2022 Scienmag- Science Magazine: Latest Science News.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In